EGFR and non-small cell lung carcinoma: Targeted therapies with tyrosine kinase inhibitors against the epidermal growth factor receptor (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) are effective to the most common treatment for NSCLC [3,4].